Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia

British Journal of Haematology

Volumn 104, Issue 2, 1999, Pages 307-312

  Pallis, M ^a,e   Turzanski, J ^a   Harrison, G ^b   Wheatley, K ^b   Langabeer, S ^c   Burnett, A K ^d   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

AML; Flow cytometry; Functional MDR; Remission rate

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE DERIVATIVE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; RHODAMINE 123; TIOGUANINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMIA REMISSION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STANDARDIZATION;

EID: 0032956842     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01157.x     Document Type: Article

References (22)

1. Beck, W.T., Grogan, T.M., Willman, C.L., Cordoncardo, C., Parham, D.M., Kuttesch, J.F., Andreeff, M., Bates, S.E., Berard, C.W., Boyett, J.M., Brophy, N.A., Broxterman, H.J., Chan, H.S.L., Dalton, W.S., Dietel, M., Fojo, A.T., Gascoyne, R.D., Head, D., Houghton, P.J., Srivastava, D.K., Lehnert, M., Leith, C.P., Paietta, E., Pavelic, Z.P., Rimsza, L., Roninson, I.B., Sikic, B.I., Twentyman, P.R., Warnke, R. & Weinstein, R. (1996) Methods to detect p-glycoprotein-associated multidrug-resistance in patients tumors: consensus recommendations. Cancer Research, 56, 3010-3020.
2. Bezombes, C., Maestre, N., Laurent, G., Levade, T., Bettaieb, A. & Jaffrezou, J.P. (1998) Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the p-glycoprotein blocker PSC833. FASEB Journal, 12, 101-109.
3. Broxterman, H.J., Sonneveld, P., Feller, N., Ossenkoppele, G., Wahrer, D.C.R., Eekman, C.A., Schoester, M., Lankelma, J., Pinedo, H.M., Lowenberg, B. & Schuurhuis, G.J. (1996) Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood, 87, 4809-4816.
4. Estey, E., Thall, P.F., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C.A., Kornblau, S., Pierce, S., Freireich, E.J., Deisseroth, A. & Keating, M. (1994) Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
5. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood, 92, 2322-2333.
6. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Schroieijers, A.B., van der Valk, P. & Scheper, R.J. (1996) Major vault protein LRP-mediated multidrug resistance. European Journal of Cancer, 32A, 979-984.
7. - cases. Blood, 86, 2329-2342.
8. Leith, C.P., Kopecky, K.J., Chen, I.M., Slovak, M., Head, D.R., Weick, J., Appelbaum, F.R. & Willman, C.L. (1997a) Frequency and clinical significance of expression of the multidrug resistance-proteins, MDR1, MRP1 and LRP, in acute myeloid leukemia patents less than 65 years old. A Southwest Oncology Group study. Blood, 90, 1733-1733.
9. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997b) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-3329.
10. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J. & Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464-2469.
11. Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1996) Biology of the multidrug resistance-associated protein, MRP. European Journal of Cancer, 32A, 945-957.
12. Marie, J.-P. (1995) P-glycoprotein in adult hematological malignancies. Hematology/Oncology Clinics of North America, 9, 239-249.
13. Michieli, M., Damiani, D., Ermacora, A., Raspadori, D., Michelutti, A., Grimaz, S., Fanin, R., Russo, D., Lauria, F., Masolini, P. & Baccarani, M. (1997) P-glycoprotein (pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells, British Journal of Haematology 96, 356-365.
14. Nuessler, V., Gullis, E., PelkaFleischer, R., delValle, F., Diem, H., Beyerlein, S., Zwierzina, H. & Wilmanns, W. (1997) Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients. Annals of Haematology, 75, 17-26.
15. Pallis, M. & Russell, N.H. (1998) Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. British Journal of Haematolgy 100, 194-197.
16. Pallis, M., Turzanski, J., Langabeer, S. & Russell, N. (1998) Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. Proceedings of the Third International Symposium on Drug Resistance in Leukaemia and Lymphoma (ed. by G. Kaspers and A. Veerman). Plenum Press.
17. Pallis, M., Zhu, Y.M. & Russell, N.H. (1997) Bcl-x(1) is heterogeneously expressed by acute myeloblastic leukemia cells and is associated with autonomous growth in vitro and with p-glycoprotein expression. Leukemia, 11, 945-949.
18. Perrot, J.Y., Faussat, A.M., Zhou, D.C., Zittoun, R., Robert, J. & Marie, J.P. (1996) Evaluation multicentrique du phenotype MDR dans les leucémies: analyse intermediare de l'experience française. Bulletin du Cancer, 83, 634-640.
19. Sonneveld, P. (1996a) Multidrug resistance in acute myeloid leukaemia. Balliere's Clinical Haematology, 9, 185-203.
20. Sonneveld, P. (1996) Reversal of multidrug-resistance in acute myeloid-leukemia and other hematological malignancies. European Journal of Cancer, 32A, 1062-1069.
21. te Boekhorst, P.A.W., Lowenberg, B., Vankapel, J., Nooter, K. & Sonneveld, P. (1995) Multidrug-resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia, 9, 1025-1031.
22. Xu, D., Knaust, E., Pisa, P., Palucka, K., Lundenberg, J., Arestrom, I., Peterson, C. & Gruber, A. (1996) Levels of mdr1 and MRP mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. British Journal of Haematology, 92, 847-854.